[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586487":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":23,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":10,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":10,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":42,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":10},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Prostatic adenocarcinoma",null,"Localized intermediate-risk prostatic adenocarcinoma",[13],"Procedure: Focal laser ablation",[15,20],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Focal laser ablation","Targeted focal laser ablation",[9],{"type":16,"name":17,"description":21,"armGroupLabels":22,"otherNames":10},"Targeted focal laser ablation of localized intermediate-risk prostate cancer",[9],{"type":24,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100586487","focal-laser-ablation-in-prostate-cancer-100586487",false,"NCT06916013","Focal Laser Ablation in Prostate Cancer","Transperineal Targeted Focal Laser Ablation of Localized Intermediate Risk Prostatic Adenocarcinoma (Pilot Study)","Inclusion Criteria:\n\n* Prostate cancer visible on mpMRI or PSMA PET\u002FCT and positive in the targeted biopsy.\n* Gleason score 7 (ISUP grade 2\u002F3)\n* PSA 10-20 ng\u002FmL\n* Clinical stage T2b\n* Refusing radical prostatectomy.\n\nExclusion Criteria:\n\n* Prostate cancer invisible on mpMRI or PSMA PET\u002FCT but positive in the systematic biopsies.\n* Presence of \\>2 MRI-visible lesions and positive in the biopsies.\n* Extracapsular extension\n* Seminal vesicle invasion\n* Presence of metastases detected by imaging\n* Gleason Score \\> 7\n* Stage \\> T2b\n* PSA \\> 20 ng\u002FmL\n* Urinary tract infection (UTI)\n* Severe lower urinary tract symptoms defined as an IPSS \\>20\n* Severe coagulation disorders\n* Inadequate compliance\n* Contraindications to MRI\n* Paramagnetic contrast agent allergy\n* Acute and\u002For chronic renal failure","MALE","45 Years",{"count":35,"type":36},30,"ESTIMATED","OBSERVATIONAL","To assess the effectiveness of MRI-US or PSMA PET\u002FCT-U\u002FS fusion-guided focal laser ablation (FLA) for the treatment of a localized, intermediate-risk prostate cancer in terms of short-term oncological \\& functional outcomes.",[40,41],"Prostate Cancer","Laser",[43,41],"Prostate cancer","NOT_YET_RECRUITING","2025-04-04",{"date":47,"type":48},"2025-04-08","ACTUAL",{"date":50,"type":36},"2025-04-20",{"date":52,"type":36},"2027-08-20",{"name":5,"class":6}]